| Size | Price | |
|---|---|---|
| 5mg | ||
| 100mg | ||
| Other Sizes |
| Targets |
The primary biological target of DHAC is DNA methyltransferase (DNMT), specifically DNMT1. By incorporating into DNA, DHAC forms a covalent bond with the enzyme, leading to its inactivation. This results in the hypomethylation of DNA and the reactivation of genes that have been silenced by aberrant methylation, a common event in tumorigenesis. This mechanism of action makes it a valuable tool for epigenetic therapy. The compound's ability to interfere with abnormal DNA methylation patterns associated with genetic instability in some tumor cells is the basis for its anticancer activity.
|
|---|---|
| ln Vitro |
Methylation experiments reveal that, in comparison to their respective controls, an LD10 dose of [3H]DHAC causes a 25.06% hypomethylation of DNA in L1210/0 cells and a 46.32% hypomethylation in a deoxycytidine kinase mutant cell line L1210/dCK(-)[2]. When cytidine triphosphate and dihydro-5-azacytidine (DHAC) compete to be incorporated into RNA, ribosome breakdown and aberrant protein synthesis result[1].
In vitro, DHAC has been shown to inhibit DNA methylation and to induce the differentiation of certain leukemia cell lines. It exhibits antiproliferative activity against various cancer cell lines, although its potency is generally lower than that of 5-azacytidine. The specific IC50 values vary depending on the cell line and the duration of exposure. It has also been shown to induce apoptosis in some cancer cells. The compound's effects on gene expression are often studied by measuring the reactivation of methylation-silenced genes, such as tumor suppressor genes, using quantitative RT-PCR. |
| ln Vivo |
Following an LD10 dose of Dihydro-5-azacytidine (DHAC; 1500 mg/kg) in tumor-bearing mice (injected with L1210/0 cells), the plasma peak concentration reached is 317 μM, and it is removed biexponentially, with a t1/ 2 α of 1.03 h and a t1/2 β of 5 h[2].
In vivo, DHAC has been evaluated in animal models of cancer, where it has demonstrated antitumor activity. It has also been tested in clinical trials, but its development was limited by its poor oral bioavailability and its rapid deamination by cytidine deaminase. To overcome these limitations, various prodrug strategies and delivery methods have been explored. The compound's pharmacokinetic properties, including its short half-life and rapid clearance, have been a challenge for its clinical development. Despite this, it remains a useful research tool for studying the effects of DNA methylation inhibition. |
| Enzyme Assay |
The non-cellular enzyme or receptor binding assay for DHAC involves measuring its ability to inhibit DNA methyltransferase activity. This is typically done using a biochemical assay with purified DNMT1 enzyme and a radiolabeled or fluorescently labeled DNA substrate. The assay measures the transfer of a methyl group from S-adenosylmethionine (SAM) to the DNA. The compound's inhibitory effect is quantified by measuring the reduction in methyl group incorporation. This type of assay is essential for confirming the compound's direct interaction with its target enzyme and for studying its mechanism of action.
|
| Cell Assay |
The in vitro cellular assay for DHAC involves treating cancer cell lines with various concentrations of the compound. The effect on DNA methylation is assessed by measuring the global level of 5-methylcytosine in DNA using a dot blot assay or by using bisulfite sequencing to analyze the methylation status of specific gene promoters. The reactivation of silenced genes is measured by quantitative RT-PCR. Antiproliferative activity is assessed using standard cell viability assays such as MTT. Apoptosis is evaluated using flow cytometry with Annexin V/PI staining. These assays are used to study the epigenetic and anticancer effects of DHAC.
|
| Animal Protocol |
The in vivo animal experiment workflow for DHAC has been established in several studies. A common approach involves the use of a xenograft model in immunodeficient mice. Cancer cells are injected subcutaneously, and once tumors form, DHAC is administered at various doses and routes (e.g., intraperitoneal, intravenous). Tumor growth is monitored by measuring tumor volume. The effect on DNA methylation in the tumor tissue is assessed by measuring global 5-methylcytosine levels or by analyzing the methylation status of specific genes. These studies have provided valuable data on the pharmacokinetics and pharmacodynamics of DHAC.
|
| Toxicity/Toxicokinetics |
Toxicity Data
Mice (intravenous injection): LD50: 2559 mg/kg |
| References |
|
| Additional Infomation |
5,6-Dihydro-5-azacytidine is a white powder. (NTP, 1992)
Dihydro-5-azacytidine is a synthetic nucleoside analog of deoxycytidine. Dihydro-5-azacytidine inhibits DNA methyltransferases, thereby interfering with abnormal DNA methylation patterns associated with genetic instability in certain tumor cells. Inhibition of this enzyme may restore the expression of tumor suppressor genes and produce antitumor activity. (NCI04) |
| Molecular Formula |
C8H14N4O5
|
|---|---|
| Molecular Weight |
246.22
|
| Exact Mass |
246.096
|
| CAS # |
62488-57-7
|
| Related CAS # |
Dihydro-5-azacytidine acetate;2470972-18-8
|
| PubChem CID |
99681
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
529.1ºC at 760 mmHg
|
| Melting Point |
360 to 365 °F (NTP, 1992)
|
| Flash Point |
273.8ºC
|
| Index of Refraction |
1.823
|
| LogP |
-2.2
|
| tPSA |
140.64
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
349
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
OCC1OC(N2CN=C(N)NC2=O)C(O)C1O
|
| InChi Key |
LJIRBXZDQGQUOO-KVTDHHQDSA-N
|
| InChi Code |
InChI=1S/C8H14N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h3-6,13-15H,1-2H2,(H3,9,10,11,16)/t3-,4-,5-,6-/m1/s1
|
| Chemical Name |
6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0614 mL | 20.3070 mL | 40.6141 mL | |
| 5 mM | 0.8123 mL | 4.0614 mL | 8.1228 mL | |
| 10 mM | 0.4061 mL | 2.0307 mL | 4.0614 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.